Epithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy.
AffiliationDepartment of Epithelial Biology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractThe proliferation rate (as assessed by Ki67 expression) and expression of oestrogen-regulated progesterone receptor (PR) was studied in normal post-menopausal breast epithelium. Normal breast epithelium from patients receiving hormone replacement therapy (HRT) at the time of surgery containing either oestrogen alone (E2) or oestrogen and progesterone combined activities (E2 + P) was also studied, as HRT has been linked to an increased breast cancer risk. Samples of breast tissue, containing normal epithelium, from 185 patients undergoing surgery for benign or malignant disease were immunocytochemically stained for PR and Ki67. The percentage of labelled cells was expressed as the labelling index (LI). The median Ki67 LI in normal post-menopausal breast epithelium was 0.19 and median PR LI was 4.75, and both were unaffected by patient age, duration of menopause or if the tissue sample originated from a breast with benign or malignant disease. Proliferation did not alter significantly in patients taking HRT (P = 0.61); however, PR expression was up-regulated in both E2 and E2 + P users (P = 0.01). The dose and duration of HRT had no effect on either parameter. A possible attenuation of sensitivity to oestradiol-induced proliferation but not to PR expression occurs in the post-menopausal breast.
CitationEpithelial proliferation and hormone receptor status in the normal post-menopausal breast and the effects of hormone replacement therapy. 1998, 78 (7):945-9 Br. J. Cancer
JournalBritish Journal of Cancer
- Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
- Authors: Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ
- Issue date: 1999 Dec
- [Hormone replacement therapy, proliferation in the breast and risk of carcinoma].
- Authors: Strnad P, Rob L, Zuntová A, Moravcová Z, Chod J, Halaska M
- Issue date: 2002 Nov
- Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
- Authors: Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E
- Issue date: 1993 Mar
- Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status.
- Authors: Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X
- Issue date: 2008 Apr
- Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.
- Authors: Salmon RJ, Ansquer Y, Asselain B, Languille O, Lesec G, Remvikos Y
- Issue date: 1999 May-Jun